Vabrinty (LEUPROLIDE ACETATE)
Vabrinty (LEUPROLIDE ACETATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Vabrinty; Generic name: LEUPROLIDE ACETATE; Manufacturer: URONOVA PHARMACEUTICALS, INC..
| Brand name | Vabrinty |
|---|---|
| Generic name | LEUPROLIDE ACETATE |
| Manufacturer | URONOVA PHARMACEUTICALS, INC. |
| Used for | 1 INDICATIONS AND USAGE VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION VABRINTY is administered subcutaneously based on the following recommended dose and schedule: 7.5 mg subcutaneously every month ( 2.1 ) 22.5 mg subcutaneously every 3 months ( 2.1 ) 30 mg subcutaneously every 4 months ( 2.1 ) 45 mg subcutaneously every 6 months ( 2.1 ) See Full Prescribing Information for preparation and administration instructions. ( 2.2 , 2.3 ) 2.1 Recommended Dosage VABRINTY is administered subcutaneously and provides continuous release of leuproli |
| Active ingredient(s) | LEUPROLIDE ACETATE |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008776cc-83f1-4f8c-819b-6471425da15f |